Home

Tutoring

Subjects

Live Classes

Study Coach

Essay Review

On-Demand Courses

Colleges

Games

Sign up

Log in

Opening subject page...

Loading your content

Practice

  • All Subjects
  • Algebra Flashcards
  • SAT Math Practice Tests
  • Math Question of the Day
  • Live Classes
  • On-Demand Courses

Varsity Tutors

  • Find a Tutor
  • Test Prep
  • Online Classes
  • K-12 Learning
  • College Search
  • VarsityTutors.com

© 2026 Varsity Tutors. All rights reserved.

← Back to quizzes

USMLE Step 1 Quiz

USMLE Step 1 Quiz: Pharmacokinetics

Practice Pharmacokinetics in USMLE Step 1 with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

Question 1 / 20

0 of 20 answered

A 48-year-old man with cirrhosis from nonalcoholic steatohepatitis is started on oral propranolol for portal hypertension prophylaxis. He develops lightheadedness and bradycardia after the first few doses. Exam: HR 48/min, BP 92/54 mm Hg. Labs: total bilirubin 3.1 mg/dL, albumin 2.8 g/dL, INR 1.7, creatinine 1.0 mg/dL. Propranolol undergoes extensive first-pass hepatic metabolism with low oral bioavailability in healthy adults; Vd ≈4 L/kg\approx 4\ \text{L/kg}≈4 L/kg and half-life ≈3\approx 3≈3–6 hours. In cirrhosis, first-pass metabolism is reduced, increasing systemic exposure after oral dosing. Which of the following best describes how the pharmacokinetics of propranolol is altered in this patient?

Select an answer to continue

What this quiz covers

This quiz focuses on Pharmacokinetics, giving you a quick way to practice the rules, question types, and explanations that matter most for USMLE Step 1.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A 48-year-old man with cirrhosis from nonalcoholic steatohepatitis is started on oral propranolol for portal hypertension prophylaxis. He develops lightheadedness and bradycardia after the first few doses. Exam: HR 48/min, BP 92/54 mm Hg. Labs: total bilirubin 3.1 mg/dL, albumin 2.8 g/dL, INR 1.7, creatinine 1.0 mg/dL. Propranolol undergoes extensive first-pass hepatic metabolism with low oral bioavailability in healthy adults; Vd ≈4 L/kg\approx 4\ \text{L/kg}≈4 L/kg and half-life ≈3\approx 3≈3–6 hours. In cirrhosis, first-pass metabolism is reduced, increasing systemic exposure after oral dosing. Which of the following best describes how the pharmacokinetics of propranolol is altered in this patient?

  1. Oral bioavailability increases due to reduced first-pass metabolism, raising AUC at the same dose (correct answer)
  2. Oral bioavailability decreases due to impaired absorption, lowering AUC at the same dose
  3. Clearance increases because hepatic enzymes are induced in cirrhosis, shortening half-life
  4. Vd decreases due to ascites, causing lower peak concentrations after oral dosing

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, the cirrhotic patient experiences propranolol toxicity from increased systemic exposure, illustrating reduced first-pass metabolism in liver disease. The correct answer, A, is based on increased oral bioavailability raising AUC, showing why bradycardia occurs at standard doses. A common misconception is decreased bioavailability from impaired absorption, as seen in B, which fails because cirrhosis primarily affects metabolism, not absorption for this drug. To teach this, focus on first-pass effects and bioavailability changes. Encourage students to compare oral vs. IV kinetics in hepatic impairment.

Question 2

A 60-year-old woman with primary biliary cholangitis and cirrhosis is started on oral morphine for severe pain. Within 24 hours she becomes increasingly sedated with shallow respirations. Exam: RR 8/min, pinpoint pupils. Labs: total bilirubin 6.0 mg/dL, albumin 2.4 g/dL, INR 2.0, creatinine 0.9 mg/dL. Morphine has significant first-pass metabolism; hepatic clearance contributes substantially to elimination, and normal half-life is ~2–3 hours. The team reviews that impaired hepatic metabolism can increase bioavailability and reduce clearance, leading to higher plasma concentrations at a given dose. Which pharmacokinetic parameter is most affected by liver disease in this patient?

  1. Increased clearance leading to reduced AUC and decreased sedation risk
  2. Decreased hepatic clearance and reduced first-pass metabolism increasing systemic exposure (correct answer)
  3. Decreased Vd causing lower peak concentrations and less respiratory depression
  4. Increased renal elimination shortening half-life and preventing accumulation

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, the patient with cirrhosis shows morphine oversedation from increased exposure, illustrating impaired hepatic clearance and reduced first-pass. The correct answer, B, is based on decreased clearance increasing systemic exposure, showing why respiratory depression ensues. A common misconception is increased clearance reducing AUC, as seen in A, which fails because cirrhosis impairs metabolism. To teach this, focus on opioid kinetics in liver disease. Encourage students to review extraction ratios and monitor for accumulation.

Question 3

A 39-year-old man with bipolar disorder is taking lithium. He develops dehydration from gastroenteritis and continues his usual dose. He presents with tremor, ataxia, and confusion. Labs: creatinine 1.8 mg/dL (baseline 0.9), BUN 38 mg/dL, sodium 150 mmol/L, lithium level 2.1 mmol/L (therapeutic 0.6–1.2). Lithium is not metabolized and is eliminated by renal excretion; reduced GFR decreases clearance and prolongs half-life. How would renal impairment alter the elimination of this drug?

  1. Decreased renal clearance prolongs half-life, increasing steady-state concentration at the same dose (correct answer)
  2. Decreased renal clearance shortens half-life by reducing tubular reabsorption
  3. Renal impairment increases first-pass metabolism, lowering lithium levels
  4. Renal impairment decreases Vd, which directly increases clearance and prevents toxicity

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, lithium toxicity from dehydration-induced AKI shows impaired excretion, illustrating reduced clearance in renal impairment. The correct answer, A, is based on decreased clearance prolonging half-life and raising levels, showing neurotoxicity. A common misconception is shortened half-life from reduced clearance, as seen in B, which fails because lower clearance extends half-life. To teach this, focus on hydration and monitoring in lithium use. Encourage students to correlate GFR with levels.

Question 4

A 24-year-old woman with epilepsy is started on intravenous phenytoin for status epilepticus and then transitioned to oral maintenance dosing. Therapeutic drug monitoring is performed. Phenytoin has Vd ≈0.7 L/kg\approx 0.7\ \text{L/kg}≈0.7 L/kg and is highly protein-bound; at therapeutic levels, elimination can approach capacity-limited kinetics. A concentration-time curve after IV loading shows an initial steep decline followed by a slower decline; later, small dose increases produce large concentration increases. Which pharmacokinetic parameter is most affected as phenytoin concentrations approach metabolic saturation?

  1. Clearance decreases as enzymes saturate, causing a disproportionate rise in steady-state concentration (correct answer)
  2. Vd increases as enzymes saturate, causing faster elimination and lower AUC
  3. Bioavailability decreases as enzymes saturate, causing higher required doses
  4. Half-life becomes shorter as concentration increases because elimination becomes first-order

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, phenytoin kinetics show saturation effects, illustrating capacity-limited elimination. The correct answer, A, is based on decreased clearance at saturation causing nonlinear rises, showing monitoring importance. A common misconception is increased Vd speeding elimination, as seen in B, which fails because saturation affects clearance, not Vd. To teach this, focus on Michaelis-Menten kinetics. Encourage students to plot concentration-dose relationships.

Question 5

A 57-year-old woman with rheumatoid arthritis is stable on oral methotrexate. She begins high-dose ibuprofen for pain. One week later, she develops mouth ulcers and fatigue. Labs: creatinine 1.6 mg/dL (baseline 0.9), BUN 32 mg/dL, AST 24 U/L, ALT 20 U/L, WBC 2.9 ×103\times 10^3×103/mcL. Methotrexate is primarily renally eliminated and is secreted by renal tubules; NSAIDs can reduce renal perfusion and compete for tubular secretion, decreasing methotrexate clearance. Which of the following best describes how the pharmacokinetics of methotrexate is altered in this patient?

  1. Decreased renal clearance increases AUC and prolongs half-life, raising toxicity risk (correct answer)
  2. Increased renal clearance decreases AUC, causing therapeutic failure
  3. Decreased absorption increases AUC by reducing first-pass metabolism
  4. Increased Vd increases clearance and prevents accumulation during chronic dosing

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, methotrexate toxicity from ibuprofen arises from renal interactions, illustrating decreased clearance causing accumulation. The correct answer, A, is based on reduced renal clearance increasing AUC and half-life, showing myelosuppression risk. A common misconception is increased clearance decreasing AUC, as seen in B, which fails because NSAIDs impair renal function. To teach this, focus on tubular secretion competitions. Encourage students to monitor for interactions.

Question 6

A 68-year-old man with cirrhosis is started on a continuous IV infusion of a hepatically metabolized sedative. The drug has Vd 40 L and normal clearance 40 L/h (half-life ≈0.693×Vd/CL≈0.7\approx 0.693\times Vd/CL \approx 0.7≈0.693×Vd/CL≈0.7 h). In this patient, clearance is estimated to be 10 L/h due to hepatic dysfunction, with Vd unchanged. No renal impairment is present. What adjustment to the dosing regimen is most appropriate given the pharmacokinetic data?

  1. Decrease the infusion rate to match reduced clearance and prevent a higher steady-state concentration (correct answer)
  2. Increase the infusion rate because reduced clearance lowers drug exposure
  3. Keep infusion rate unchanged because Vd, not clearance, determines steady-state concentration
  4. Increase dosing frequency because longer half-life shortens time to steady state

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, sedative infusion in cirrhosis requires adjustment for lower clearance, illustrating steady-state dependence on infusion rate and clearance. The correct answer, A, is based on decreasing rate to maintain target concentration, showing prevention of excess. A common misconception is increasing rate for reduced clearance, as seen in B, which fails because lower clearance raises steady-state levels. To teach this, focus on Css = rate/CL equation. Encourage students to calculate adjustments using kinetics.

Question 7

A 45-year-old man with CKD stage 4 is prescribed a renally eliminated antiviral. The drug follows first-order kinetics and has Vd 30 L. In healthy adults, clearance is 6 L/h (half-life ≈3.5\approx 3.5≈3.5 h). In this patient, measured clearance is 2 L/h due to reduced GFR. No hepatic disease. Which of the following best describes how the pharmacokinetics of this drug is altered in this patient?

  1. Half-life increases because clearance decreases while Vd remains constant (correct answer)
  2. Half-life decreases because reduced clearance lowers plasma concentration more quickly
  3. Bioavailability increases because renal impairment reduces first-pass hepatic metabolism
  4. Vd decreases and therefore AUC decreases despite reduced clearance

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, a patient with chronic kidney disease receiving a renally eliminated antiviral illustrates the impact of decreased clearance on half-life. The correct answer, Choice A, is based on the half-life formula (t1/2 = 0.693 * Vd / CL), showing that decreased clearance with constant Vd leads to increased half-life. A common misconception is that reduced clearance accelerates drug elimination, as seen in Choice B, which fails because reduced clearance actually prolongs the drug's presence in the plasma. To teach this, focus on renal elimination pathways and how they are impaired in kidney disease. Encourage students to calculate half-life using given parameters and apply concepts to dosing adjustments in renal impairment.

Question 8

A 64-year-old woman with CKD stage 4 is started on intravenous vancomycin for MRSA bacteremia. Weight 80 kg. Labs: creatinine 2.4 mg/dL, estimated GFR 24 mL/min/1.73 m2^22, AST 22 U/L. Vancomycin has Vd ≈0.7 L/kg\approx 0.7\ \text{L/kg}≈0.7 L/kg and is primarily eliminated unchanged by the kidneys; therapeutic monitoring targets an AUC/MIC goal. After a standard regimen, a measured trough concentration is 28 mcg/mL (goal often 10–20 depending on indication), suggesting accumulation. What adjustment to the dosing regimen is most appropriate given the pharmacokinetic data?

  1. Increase dose frequency to reduce AUC and lower trough concentrations
  2. Reduce total daily dose by lowering dose and/or extending interval due to decreased renal clearance (correct answer)
  3. Increase the loading dose repeatedly because Vd is the main determinant of steady-state trough
  4. Switch to oral dosing to bypass renal elimination and shorten half-life

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, high vancomycin trough in CKD indicates accumulation, illustrating reduced renal clearance. The correct answer, B, is based on reducing dose or extending interval, showing how to achieve target AUC. A common misconception is increasing frequency to lower AUC, as seen in A, which fails because it would worsen accumulation. To teach this, focus on TDM in renal impairment. Encourage students to calculate AUC from troughs.

Question 9

A 55-year-old woman with alcohol-associated cirrhosis (Child-Pugh C) is treated for anxiety with oral diazepam. She reports progressive daytime somnolence after 5 days on a typical outpatient dose. Exam shows asterixis and mild confusion. Labs: total bilirubin 4.0 mg/dL, albumin 2.6 g/dL, INR 1.9, AST 110 U/L, ALT 70 U/L, creatinine 0.8 mg/dL. Diazepam is highly lipophilic with large Vd (≈1.0 L/kg\approx 1.0\ \text{L/kg}≈1.0 L/kg), high plasma protein binding, and primarily hepatic oxidative metabolism to active metabolites; normal half-life is 30–50 hours. A trough concentration drawn before the next dose is higher than expected for the prescribed regimen. The clinician recalls that reduced hepatic metabolism decreases clearance and prolongs half-life, and that time to steady state increases with longer half-life. What adjustment to the dosing regimen is most appropriate given the pharmacokinetic data?

  1. Increase the dosing frequency to reach steady state sooner despite liver disease
  2. Decrease the dose and/or extend the dosing interval to account for reduced clearance (correct answer)
  3. Switch to a higher Vd drug to increase clearance and shorten half-life
  4. Increase the dose because higher protein binding lowers free drug in cirrhosis

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, the patient with severe cirrhosis develops diazepam toxicity from prolonged half-life and accumulation, illustrating reduced hepatic clearance in liver disease. The correct answer, B, is based on decreasing dose or extending interval to match reduced clearance, showing how to prevent oversedation. A common misconception is increasing frequency to hasten steady state, as seen in A, which fails because longer half-life delays steady state regardless. To teach this, focus on half-life prolongation in cirrhosis and dosing adjustments. Encourage students to use therapeutic monitoring and simulate accumulation scenarios.

Question 10

A 70-year-old man with atrial fibrillation is taking oral warfarin (stable INR 2.3). He begins trimethoprim-sulfamethoxazole for a urinary tract infection. Four days later, he presents with epistaxis and gingival bleeding. Labs: INR 6.1, hemoglobin 12.8 g/dL, creatinine 1.0 mg/dL, AST 28 U/L, ALT 24 U/L, albumin 4.1 g/dL. Warfarin is highly albumin-bound and primarily cleared by hepatic metabolism; its half-life is ~36 hours. The clinician suspects a drug-drug interaction affecting clearance and/or free fraction. Which of the following best describes how the pharmacokinetics of warfarin is altered in this patient?

  1. Enzyme inhibition decreases hepatic clearance, increasing AUC and prolonging effective half-life (correct answer)
  2. Enzyme induction increases clearance, decreasing AUC and lowering INR
  3. Reduced absorption decreases bioavailability, increasing INR due to higher potency
  4. Increased Vd decreases free drug and reduces bleeding risk despite higher INR

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, warfarin bleeding from interaction with trimethoprim-sulfamethoxazole arises from enzyme inhibition, illustrating reduced clearance elevating INR. The correct answer, A, is based on inhibition decreasing clearance and increasing AUC, showing why anticoagulation intensifies. A common misconception is enzyme induction increasing clearance, as seen in B, which fails because this interaction inhibits metabolism. To teach this, focus on CYP interactions and monitoring. Encourage students to predict interaction outcomes using kinetic principles.

Question 11

A 52-year-old man with cirrhosis is prescribed an oral drug with high first-pass metabolism and low baseline bioavailability (F ~0.2). He has no renal impairment. After initiation, measured plasma concentrations are substantially higher than predicted. Labs: bilirubin 4.5 mg/dL, albumin 2.7 g/dL, INR 1.9. The clinician suspects reduced first-pass metabolism and reduced hepatic clearance. Which pharmacokinetic parameter is most affected by this condition in this patient?

  1. Increased bioavailability due to reduced first-pass metabolism, increasing AUC at the same oral dose (correct answer)
  2. Decreased bioavailability due to impaired absorption, decreasing AUC at the same oral dose
  3. Increased clearance due to hepatic enzyme induction, lowering AUC and prolonging half-life
  4. Decreased Vd causing lower peak concentrations and reduced toxicity risk

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, high first-pass drug in cirrhosis yields higher concentrations, illustrating reduced metabolism increasing bioavailability. The correct answer, A, is based on increased F raising AUC, showing exposure elevation. A common misconception is decreased bioavailability from absorption impairment, as seen in B, which fails because cirrhosis enhances systemic availability. To teach this, focus on portal shunting effects. Encourage students to model first-pass changes.

Question 12

A 62-year-old man with chronic hepatitis C and decompensated cirrhosis (ascites, jaundice) is admitted for cellulitis. He is started on intravenous lidocaine for ventricular ectopy. Baseline vitals are stable. Exam shows scleral icterus and shifting dullness. Labs: total bilirubin 5.2 mg/dL, albumin 2.3 g/dL, INR 2.1, AST 88 U/L, ALT 64 U/L, creatinine 0.9 mg/dL. Lidocaine is a high hepatic extraction drug with extensive first-pass metabolism (oral bioavailability low), Vd ≈1.1 L/kg\approx 1.1\ \text{L/kg}≈1.1 L/kg, and normal adult clearance ≈10 mL/min/kg\approx 10\ \text{mL/min/kg}≈10 mL/min/kg with half-life ≈1.5\approx 1.5≈1.5 hours. Six hours after starting a continuous infusion at a standard rate, a steady-state concentration is not achieved and measured plasma concentration is 2.8 mcg/mL (target 1.5–5 mcg/mL), but by 18 hours the concentration rises to 6.2 mcg/mL with new confusion and perioral numbness. No interacting drugs are given. Given reduced hepatic blood flow and impaired metabolic capacity in cirrhosis, the team reviews that for high-extraction drugs, clearance is flow-limited and decreases with reduced hepatic perfusion, prolonging half-life and increasing accumulation during infusion. Which pharmacokinetic parameter is most affected by liver disease in this patient?

  1. Increased Vd from ascites causes faster elimination and a shorter half-life
  2. Decreased hepatic clearance due to reduced hepatic blood flow increases half-life and accumulation (correct answer)
  3. Increased renal clearance compensates for hepatic dysfunction and lowers steady-state concentration
  4. Increased oral bioavailability reduces AUC by enhancing first-pass metabolism

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, the patient with decompensated cirrhosis experiences lidocaine accumulation due to reduced hepatic blood flow and impaired metabolism, illustrating flow-limited clearance for high-extraction drugs. The correct answer, B, is based on decreased hepatic clearance increasing half-life and accumulation, showing why toxicity develops during infusion. A common misconception is that increased Vd from ascites speeds elimination, as seen in A, which fails because Vd affects distribution, not clearance for hepatically cleared drugs. To teach this, focus on extraction ratios and how liver disease alters them. Encourage students to analyze infusion kinetics and adjust doses in hepatic impairment.

Question 13

A 58-year-old woman with epilepsy is stable on oral phenytoin with a total phenytoin concentration of 12 mcg/mL (therapeutic 10–20). She starts oral fluconazole for candidiasis. One week later she develops nystagmus and ataxia. Labs: total phenytoin 22 mcg/mL, albumin 4.0 g/dL, creatinine 0.9 mg/dL, AST 30 U/L. Phenytoin is hepatically metabolized and exhibits capacity-limited (zero-order) elimination at higher concentrations; small dose changes can cause disproportionate concentration increases. Which of the following best describes how the pharmacokinetics of phenytoin is altered in this patient?

  1. Enzyme inhibition reduces metabolic clearance, increasing steady-state concentration disproportionately (correct answer)
  2. Enzyme induction increases clearance, raising phenytoin levels and causing toxicity
  3. Increased absorption decreases AUC because first-pass metabolism is enhanced
  4. Decreased Vd increases clearance, shortening half-life and causing withdrawal seizures

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, phenytoin toxicity from fluconazole interaction results from enzyme inhibition, illustrating nonlinear kinetics amplification. The correct answer, A, is based on reduced clearance causing disproportionate concentration rise, showing saturation effects. A common misconception is enzyme induction increasing clearance, as seen in B, which fails because fluconazole inhibits CYP enzymes. To teach this, focus on zero-order elimination. Encourage students to interpret levels in nonlinear scenarios.

Question 14

A 63-year-old man with chronic back pain takes oral oxycodone. His physician starts rifampin for latent tuberculosis. Two weeks later, the patient reports markedly reduced analgesia despite adherence. Vitals are stable; no new findings. Labs: AST 26 U/L, ALT 22 U/L, creatinine 0.9 mg/dL. Oxycodone is primarily cleared by hepatic metabolism; normal half-life is ~3–4 hours. Rifampin is a potent inducer of hepatic drug-metabolizing enzymes, increasing clearance and reducing plasma concentrations. What adjustment to the dosing regimen is most appropriate given the pharmacokinetic data?

  1. Decrease the oxycodone dose because induction increases AUC and toxicity risk
  2. Increase the oxycodone dose or switch to a non–enzyme-metabolized analgesic due to increased clearance (correct answer)
  3. Extend the dosing interval because clearance is reduced and half-life is prolonged
  4. No change is needed because enzyme induction only affects absorption, not clearance

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, reduced oxycodone efficacy from rifampin arises from enzyme induction, illustrating increased clearance lowering exposure. The correct answer, B, is based on increasing dose or switching to compensate for induction, showing how to restore analgesia. A common misconception is decreasing dose for increased AUC, as seen in A, which fails because induction reduces AUC. To teach this, focus on inducers' effects on metabolism. Encourage students to adjust regimens in induction cases.

Question 15

A 65-year-old woman with CKD stage 3 is treated with a renally eliminated antibiotic that follows first-order kinetics. The drug’s normal clearance is 100 mL/min and half-life 4 hours when GFR is normal. Her measured creatinine clearance is 50 mL/min, and hepatic function is normal. Assuming Vd is unchanged, the team estimates new clearance and half-life to guide dosing. Which of the following best describes how the pharmacokinetics of this drug is altered in this patient?

  1. Clearance decreases roughly in proportion to creatinine clearance, increasing half-life and AUC (correct answer)
  2. Clearance increases because reduced filtration triggers compensatory hepatic elimination
  3. Half-life decreases because reduced clearance lowers plasma concentration faster
  4. Bioavailability decreases because renal impairment increases first-pass metabolism

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, antibiotic in CKD shows altered elimination, illustrating clearance proportional to GFR. The correct answer, A, is based on decreased clearance increasing half-life and AUC, showing dosing adjustment needs. A common misconception is increased clearance from hepatic compensation, as seen in B, which fails because the drug is renally eliminated. To teach this, focus on clearance estimation from CrCl. Encourage students to predict half-life changes.

Question 16

A 67-year-old man with CKD stage 4 is started on oral gabapentin for neuropathic pain. After 1 week, he reports profound sedation and dizziness. Labs: creatinine 2.8 mg/dL, estimated GFR 20 mL/min/1.73 m2^22, AST 18 U/L, ALT 16 U/L. Gabapentin is not significantly metabolized and is eliminated unchanged by the kidneys; normal half-life is ~5–7 hours but increases markedly when GFR is reduced. Which of the following best describes how the pharmacokinetics of gabapentin is altered in this patient?

  1. Half-life is prolonged due to reduced renal clearance, increasing AUC at the same dose (correct answer)
  2. Half-life is shortened due to decreased filtration, reducing exposure and efficacy
  3. Bioavailability increases because renal failure enhances intestinal absorption
  4. Vd decreases and therefore clearance increases, preventing accumulation

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, gabapentin sedation in CKD stems from accumulation, illustrating prolonged half-life from reduced renal clearance. The correct answer, A, is based on extended half-life increasing AUC, showing why dosing must be reduced. A common misconception is shortened half-life from decreased filtration, as seen in B, which fails because reduced clearance prolongs half-life. To teach this, focus on renally cleared drugs in CKD. Encourage students to use dosing guidelines based on GFR.

Question 17

A 44-year-old man with advanced cirrhosis is treated with intravenous midazolam for procedural sedation. After a standard bolus, he remains sedated longer than expected. Exam is otherwise unremarkable. Labs: total bilirubin 3.8 mg/dL, albumin 2.5 g/dL, INR 1.8, creatinine 0.7 mg/dL. Midazolam is highly protein-bound and primarily cleared by hepatic metabolism; normal clearance is ~400 mL/min with half-life ~2 hours in healthy adults. In this patient, measured clearance is estimated at 150 mL/min from concentration-time sampling. Which of the following best describes how the pharmacokinetics of midazolam is altered in this patient?

  1. Half-life is shortened because reduced clearance decreases drug exposure
  2. Half-life is prolonged because hepatic clearance is reduced, increasing AUC for a given dose (correct answer)
  3. Vd is decreased, which necessarily increases clearance and shortens sedation duration
  4. Bioavailability is reduced after IV dosing due to first-pass metabolism

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, prolonged midazolam sedation in cirrhosis stems from reduced clearance, illustrating hepatic metabolism impairment. The correct answer, B, is based on prolonged half-life increasing AUC, showing why recovery is delayed. A common misconception is shortened half-life from reduced clearance, as seen in A, which fails because lower clearance extends half-life. To teach this, focus on clearance-half-life relationships. Encourage students to calculate parameters from concentration data.

Question 18

A 41-year-old man is given a single oral dose of a drug and, on a separate day, an equivalent IV dose. The measured AUC after oral dosing is 60 mg·h/L, and the AUC after IV dosing is 120 mg·h/L. The drug has linear kinetics and identical clearance on both days. The clinician asks what the AUC indicates about the drug’s bioavailability. What does the area under the curve (AUC) indicate about the bioavailability of this drug?

  1. Bioavailability is 50% because F=AUCoral/AUCIVF=\text{AUC}_{oral}/\text{AUC}_{IV}F=AUCoral​/AUCIV​ when doses are equal (correct answer)
  2. Bioavailability is 200% because oral dosing always yields higher AUC than IV dosing
  3. Bioavailability cannot be estimated from AUC because AUC reflects potency, not exposure
  4. Bioavailability is 50% because Vd doubles after oral dosing, reducing AUC by half

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, lower oral AUC compared to IV indicates incomplete absorption, illustrating bioavailability calculation. The correct answer, A, is based on F as oral/IV AUC ratio, showing 50% bioavailability. A common misconception is 200% bioavailability from higher oral AUC, as seen in B, which fails because oral AUC is lower. To teach this, focus on AUC interpretations. Encourage students to compare routes in studies.

Question 19

A 66-year-old woman with chronic kidney disease (CKD) stage 4 presents with pneumonia and is started on intravenous gentamicin. She weighs 60 kg. Labs: creatinine 2.6 mg/dL, BUN 46 mg/dL, estimated GFR 22 mL/min/1.73 m2^22, AST 24 U/L, ALT 20 U/L. Gentamicin is hydrophilic with Vd ≈0.25 L/kg\approx 0.25\ \text{L/kg}≈0.25 L/kg and is eliminated almost entirely by glomerular filtration; normal half-life is ~2 hours with normal renal function. Twelve hours after a standard dose, the measured concentration remains elevated. How would renal impairment alter the elimination of this drug?

  1. Decreased renal clearance prolongs half-life, increasing trough concentrations and accumulation risk (correct answer)
  2. Decreased renal clearance shortens half-life because less drug is filtered into urine
  3. Renal impairment primarily decreases Vd, lowering peak concentrations after IV dosing
  4. Renal impairment increases first-pass metabolism, reducing AUC and toxicity risk

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, elevated gentamicin levels in CKD result from impaired excretion, illustrating reduced renal clearance. The correct answer, A, is based on decreased clearance prolonging half-life and raising troughs, showing ototoxicity risk. A common misconception is shortened half-life from reduced clearance, as seen in B, which fails because lower clearance extends half-life. To teach this, focus on GFR-drug clearance relationships. Encourage students to use nomograms for dosing.

Question 20

A 59-year-old man with atrial fibrillation is started on intravenous amiodarone. He later transitions to oral dosing. Amiodarone is highly lipophilic with very large Vd (>50 L/kg>50\ \text{L/kg}>50 L/kg) and a very long terminal half-life (weeks) due to extensive tissue distribution and slow release. After stopping therapy because of bradycardia, the patient continues to have drug effects for several weeks. Which pharmacokinetic parameter best explains the prolonged persistence of drug effect after discontinuation?

  1. Very large Vd with slow redistribution prolongs terminal half-life and delays elimination (correct answer)
  2. High oral bioavailability causes faster clearance and shorter terminal half-life
  3. Low protein binding increases renal filtration and rapidly clears the drug
  4. First-pass metabolism increases AUC and shortens time to steady state

Explanation: This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, prolonged amiodarone effects post-discontinuation arise from tissue storage, illustrating large Vd and long half-life. The correct answer, A, is based on large Vd prolonging terminal half-life, showing persistence reasons. A common misconception is high bioavailability causing faster clearance, as seen in B, which fails because bioavailability affects exposure, not elimination duration. To teach this, focus on multi-compartment models. Encourage students to consider redistribution in lipophilic drugs.